Airway Inflammometry For Asthma And COPD: Practitioner Fellowship Peter G Gibson
Funder
National Health and Medical Research Council
Funding Amount
$568,892.00
Summary
Asthma and chronic obstructive pulmonary disease will receive the benefits of personalized medicine with this Fellowship funding. Dr Gibson, an international leader in this field, has identified key biomarkers that will allow treatments to be rationalized based on the underlying disease mechanisms. This research will translate the benefits on modern technology and apply these to individualized care for people with asthma and COPD, who can expect fewer lung attacks and better quality of life.
National Clinical Centre Of Research Excellence In Severe Asthma
Funder
National Health and Medical Research Council
Funding Amount
$2,597,952.00
Summary
Severe Asthma remains a large burden for the Australian community. It does not respond to current management approaches. We will develop and implement a targetted therapy approach to severe asthma that will involve assessment of needs of people with severe asthma, community burden form severe asthma, biomarkers and linked treatment strategies, as well as knowledge transfer tools and training of the health and medical workforce.
Predicting The Successful Resolution Of Obstructive Sleep Apnoea Following Weight-loss Surgery
Funder
National Health and Medical Research Council
Funding Amount
$729,284.00
Summary
The current project aims to determine how obesity causes obstructive sleep apnoea (OSA), a disorder associated with significant cardiovascular morbidity & mortality. This research is a burgeoning area given that obesity is one of the western world’s leading health care concerns. Our findings may ultimately offer a refinement of weight-loss interventions to maximise their effects on OSA as well as offering novel treatment strategies in the management of this disorder that is desperately needed.
Heterogeneity Of Airway Smooth Muscle Remodelling In Asthma
Funder
National Health and Medical Research Council
Funding Amount
$623,078.00
Summary
Increased smooth muscle in the airways causes excessive narrowing and asthma symptoms. The distribution of the increased muscle in the lung varies between people with asthma and may determine how severe the asthma is and what treatments are best. This project will use tissues from many cases of asthma to map this distribution and will use laser scanning in the airways to develop a test to safely examine the smooth muscle in living people, in order to better treat or prevent asthma.
Genomic Adaptation Of Pseudomonas Aeruginosa In The Cystic Fibrosis Airway
Funder
National Health and Medical Research Council
Funding Amount
$133,351.00
Summary
Pseudomonas aeruginosa (Pa) is an important respiratory pathogen in Cystic Fibrosis (CF) which causes substantial morbidity and mortality. Its genetic versatility enables it to thrive in a wide diversity of environment. This study aims to assess the genomic adaptation of the common Pa strains among the Australian CF patients during chronic infection and during intravenous antibiotics therapy. The study results can lead to development of novel treatment options for Pa infection in CF.
Modulation Of Macrophage Function As A Therapy For Chronic Obstructive Pulmonary Disease (COPD)
Funder
National Health and Medical Research Council
Funding Amount
$435,589.00
Summary
We have established that defective clearance of dying cells by phagocytes in the airway can a) perpetuate inflammation in smokers with-without COPD and b) be improved by administration of therapies (Mannose binding lectin and Procysteine) in a mouse model. The current proposal specifically addresses the role of phagocytes in the ongoing airway damage in our COPD patients, and more thoroughly investigates the mechanisms and effects of administration of relevant new therapies (in a mouse model).
Macrophages, Sugars And Innate Immunity In Chronic Lung Inflammation
Funder
National Health and Medical Research Council
Funding Amount
$413,150.00
Summary
This project is about a new idea to treat severe asthma, chronic obstructive lung disease (COPD) and sudden worsening of these diseases (exacerbations). Asthma and COPD are very common. Asthma afflicts approximately 10 % of all Australians and kills approximately 700 annually. COPD will be the third most common cause of death worldwide by 2010 (WHO) and costs more that $ AUS 10 Billion annually. The highest risk of death and greatest costs are associated with severe asthma and exacerbations. Our ....This project is about a new idea to treat severe asthma, chronic obstructive lung disease (COPD) and sudden worsening of these diseases (exacerbations). Asthma and COPD are very common. Asthma afflicts approximately 10 % of all Australians and kills approximately 700 annually. COPD will be the third most common cause of death worldwide by 2010 (WHO) and costs more that $ AUS 10 Billion annually. The highest risk of death and greatest costs are associated with severe asthma and exacerbations. Our idea, which is based on extensive animal data, is that these diseases can be treated by blocking the activity of proteins that allow a cell called the lung macrophage to grow, become activated, proliferate and survive. These proteins are called CSF-1 and GM-CSF and they belong to a larger class of proteins called colony stimulating factors (CSFs) Macrophages are important because they can rapidly respond to bacteria, viruses and fungi that can infect the lungs of asthma and COPD patients. Infections cause exacerbations. Normally, macrophages release a number of molecules called mediators that rouse a strong defensive reaction- a process called innate immunity. For example macrophages signal for a cell type called the neutrophil, which is a very efficient bacteria killer, to flood into the lung. However, these same cells can cause serious lung damage if the response is too strong or persistent. Macrophages and neutrophils need CSFs to work properly so blocking CSFs prevents lung damage. Although we now already know that blocking CSFs can prevent and reverse lung inflammation we still need to know a great deal more in order to know if this approach will be useful to treat people in the future. Our project is therefore all about understanding the fine detail of how CSFs can damage the lung. The importance of the project is that our work may lead to entirely new, and much more effective, treatments for people suffering from asthma and COPD.Read moreRead less